Natural History of Arrhythmogenic Right Ventricular Cardiomyopathy in the Boxer Dog: a Prospective Study
Overview
Veterinary Medicine
Affiliations
Background: Boxer arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease that may result in sudden death or heart failure.
Hypothesis/objectives: To prospectively study the natural history of Boxer ARVC.
Animals: 72 dogs (49 ARVC, 23 controls).
Methods: Boxers >1 year of age were recruited for annual reevaluation. CONTROLS were defined as being ≥6 years of age and having <50 ventricular premature complex (VPCs)/24 h. ARVC was defined as ≥300 VPCs/24 h in the absence of other disease. Dogs were genotyped for the striatin deletion when possible. Descriptive statistics were determined for age; VPC number; annual change in VPC number; and left ventricular (LV) echocardiographic dimensions. Survival time was calculated.
Results: Controls: median age of 7 years (range, 6-10); number of VPCs 12 (range, 4-32). Median time in study of 6 years (range, 2-9). Seventeen of 23 were genotyped (5 positive, 12 negative). ARVC: median age of diagnosis of 6 (range, 1-11). Median time in study 5 years (range, 3-8). A total of 33% were syncopal and 43/49 were genotyped (36 positive, 7 negative). Yearly change in VPCs was 46 (range, -7,699 to 33,524). Annual percentage change in LV dimensions was 0, and change in fractional shortening (FS%) was 2%. Two dogs had FS% <20%. Although ARVC dogs died suddenly, there was no difference in survival time between groups. ARVC median age of survival was 11 years, and for controls was 10 years.
Conclusions/clinical Importance: Arrhythmogenic right ventricular cardiomyopathy is a disease of middle age and frequently is associated with the striatin deletion. Syncope occurs in approximately 1/3 of affected dogs; systolic dysfunction is uncommon. The prognosis in many affected dogs is good.
Investigation of the cardiac effects of exercise testing on apparently healthy Boxer dogs.
Agarwal D, Cote E, OSullivan L, Meurs K, Steiner J J Vet Intern Med. 2023; 37(5):1667-1678.
PMID: 37578273 PMC: 10472998. DOI: 10.1111/jvim.16830.
The Role of Personalized Medicine in Companion Animal Cardiology.
Rivas V, Stern J, Ueda Y Vet Clin North Am Small Anim Pract. 2023; 53(6):1255-1276.
PMID: 37423841 PMC: 11184409. DOI: 10.1016/j.cvsm.2023.05.016.
Evaluation of autoantibodies to desmoglein-2 in dogs with and without cardiac disease.
Walker A, Li R, Nguyen N, Jauregui C, Meurs K, Gagnon A Sci Rep. 2023; 13(1):5044.
PMID: 36977772 PMC: 10043840. DOI: 10.1038/s41598-023-32081-x.
Crooks A, Hsue W, Tschabrunn C, Gelzer A J Vet Intern Med. 2022; 36(3):886-896.
PMID: 35307868 PMC: 9151449. DOI: 10.1111/jvim.16412.
A review of the underlying genetics and emerging therapies for canine cardiomyopathies.
Shen L, Estrada A, Meurs K, Sleeper M, Vulpe C, Martyniuk C J Vet Cardiol. 2021; 40:2-14.
PMID: 34147413 PMC: 8606013. DOI: 10.1016/j.jvc.2021.05.003.